精准医学背景下心力衰竭患者生物标志物临床应用的前景及挑战  

Prospects and challenges of clinical application of biomarkers in patients with heart failure in precision medicine

作　　者：贾克刚[1] Jia Kegang(Department of Clinical Laboratory,Tianjin Medical University Cardiovascular College,TEDA International Cardiovascular Hospital,Tianjin 300457,China)

机构地区：[1]天津医科大学心血管病临床学院泰达国际心血管病医院检验科,天津300457

出　　处：《中华检验医学杂志》2023年第12期1217-1223,共7页Chinese Journal of Laboratory Medicine

基　　金：天津市泰达国际心血管病医院院级项目(2022-TD-010);天津市滨海新区卫生健康委科技项目(2022BWKZ002);天津市医学重点学科(专科)建设项目资助内科学(心血管病学)-TJYXZDXK-020A。

摘　　要：精准医学时代的到来开启了心力衰竭(HF)新型诊疗模式,各种组学技术的发展也促进了HF精准表型的研究和临床应用。HF患者受性别、年龄、身高、体重、药物、瓣膜病等诸多因素影响,同时其病程较长,病情复杂,不同的HF分型与分期也影响患者的治疗和预后。因而,临床上急需各种新型生物标志物以满足HF个体化诊疗的需要。随着表观遗传学、蛋白质组学、代谢组学和微生物学的最新进展,为HF个体异质性研究提供“加法”的有益补充作用。讨论现阶段各类型标志物尚存的应用问题和局限性。为未来,将所有个体化组学数据进行整合,为HF患者的精准医疗提供无限潜力。The arrival of the era of precision medicine has opened a new diagnosis and treatment model for heart failure(HF),and the development of various omics technologies has also promoted the research and clinical application of HF precision phenotype.HF patients are affected by many factors such as gender,age,height,weight,drugs,valvular disease,etc.At the same time,its disease course is long and complex,and different HF types and stages also affect the treatment and prognosis of patients.Therefore,a variety of new biomarkers are urgently needed in clinic to meet the needs of individualized HF diagnosis and treatment.With the latest advances in epigenetics,proteomics,metabolomics and microbiology,it provides a beneficial complementary effect of"addition"for the study of HF individual heterogeneity.The existing application problems and limitations of various types of markers are discussed.For the future,the integration of all personalized omics data offers unlimited potential for precision medicine in patients with HF.

关 键 词：心力衰竭 生物标志物 异质性 精准医学 

分 类 号：R541.6[医药卫生—心血管疾病]